IL6 110
Alternative Names: IL6-110Latest Information Update: 06 Jun 2024
At a glance
- Originator Ildong Pharmaceutical
- Developer Ildong Pharmaceutical; iLeadBMS
- Class Antineoplastics
- Mechanism of Action Cyclin dependent kinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Gastric cancer
Most Recent Events
- 26 Feb 2024 Preclinical trials in Breast cancer in South Korea (unspecified route)
- 26 Feb 2024 Preclinical trials in Gastric cancer in South Korea (unspecified route)
- 26 Feb 2024 Pharmacodynamics data from preclinical trial in Gastric cancer and Breast cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024